AgeX Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 22, 2024
SER$1.430.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
| Year Ended December 31, | ||||
|---|---|---|---|---|
| 2023 · 2022 | ||||
| OPERATING ACTIVITIES: | ||||
| Net loss attributable to AgeX | $(14,803) | $(10,462) | ||
| Net loss attributable to noncontrolling interest | (8) | (60) | ||
| Adjustments to reconcile net loss attributable to AgeX to net cash used in operating activities: | ||||
| Change in fair value of warrants | 35 | 225 | ||
| Amortization of intangible assets | 131 | 132 | ||
| Amortization of debt issuance costs | 5,285 | 3,137 | ||
| Stock-based compensation | 648 | 760 | ||
| Gain on disposition of fixed assets | (73) | - | ||
| Write off of prepaid shelf registration statement related expenses | 360 | - | ||
| Changes in operating assets and liabilities: | ||||
| Accounts and grants receivable | (53) | 21 | ||
| Prepaid expenses and other current assets | 1,092 | 896 | ||
| Interest on convertible note receivable | (554) | - | ||
| Accounts payable and accrued liabilities | 1,150 | 144 | ||
| Related party payables | 69 | 255 | ||
| Insurance premium liability | (1,075) | (983) | ||
| Other current liabilities | (4) | (4) | ||
| Net cash used in operating activities | (7,800) | (5,939) | ||
| INVESTING ACTIVITIES: | ||||
| Cash advanced on convertible note receivable | (10,000) | - | ||
| Net cash used in investing activities | (10,000) | - | ||
| FINANCING ACTIVITIES: | ||||
| Draw down on loan facilities from Juvenescence | 17,500 | 6,000 | ||
| Net cash provided by financing activities | 17,500 | 6,000 | ||
| NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | (300) | 61 | ||
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH: | ||||
| At beginning of the year | 695 | 634 | ||
| At end of the year | $395 | $695 | ||
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: | ||||
| Cash paid during the year for interest | $27 | $14 | ||
| SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES: | ||||
| Issuance of preferred stock in exchange for debt | $36,000 | $ | - | |
| Issuance of common stock upon vesting of restricted stock units (Note 8) | $2 | $8 | ||
| Issuance of warrants for debt issuance under the 2020 Loan Agreement | $ | - | $178 | |
| Fair value of liability classified warrants at debt inception date (Note 6) | $663 | $4,148 | ||
| Debt refinanced with new debt (Note 5) | $ | - | $7,160 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.